HLA-B*5701 testing to predict abacavir hypersensitivity | Zendy

D. Joseph | Zendy; Kelly C. Lee | Zendy; Grace m. Kuo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HLA-B*5701 testing to predict abacavir hypersensitivity

Author(s) -

D. Joseph,

Kelly C. Lee,

Grace m. Kuo

Publication year - 2010

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1203

Subject(s) - abacavir , medicine , human leukocyte antigen , hla b , allele , immunology , reverse transcriptase inhibitor , hypersensitivity reaction , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , biology , genetics , antigen , gene

Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B*5701. A screening test for the HLA-B*5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research